Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminated
NCT04552899Phase 3Updated Apr 18, 2024
Sponsor: Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
United States, Argentina, Australia, Austria, Belgium +30 more
Prospective Single-Timepoint Huntington's Disease Biospecimen Collection StudyUnknown
NCT05773196N/AUpdated Apr 18, 2024
Sponsor: Sanguine Biosciences
Huntington Disease · Huntington's Dementia · Huntington Disease, Late Onset · Huntington; Dementia (Etiology)
United States
Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)Completed
NCT05401565Phase 2Updated Apr 18, 2024
Sponsor: Hoffmann-La Roche
Stress Disorders, Post-Traumatic
United States
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer PatientsCompleted
NCT03272477Phase 2Updated Apr 17, 2024
Sponsor: Palleos Healthcare GmbH
Breast Neoplasms
Germany
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).Unknown
NCT05240131Phase 1, Phase 2Updated Apr 12, 2024
Sponsor: Galecto Biotech AB
Non-Small Cell Lung Cancer
France, Poland, Spain
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System MetastasesCompleted
NCT03625141Phase 2Updated Apr 11, 2024
Sponsor: Hoffmann-La Roche
Metastatic Melanoma
Brazil, France, Germany, Hungary, Italy +3 more
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboActive Not Recruiting
NCT03281954Phase 3Updated Apr 8, 2024
Sponsor: NSABP Foundation Inc
Triple Negative Breast Cancer
United States, Canada
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary TractCompleted
NCT02928406Phase 3Updated Apr 4, 2024
Sponsor: Hoffmann-La Roche
Urinary Tract Cancer
Argentina, Australia, Austria, Belgium, Brazil +27 more
An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular LymphomaCompleted
NCT03817853Phase 4Updated Apr 4, 2024
Sponsor: Hoffmann-La Roche
Advanced Follicular Lymphoma
United States, Brazil, Germany, Japan, Netherlands +2 more
Does the AMH Concentration Depend on the Menstrual Cycle?Completed
NCT06330259N/AUpdated Apr 1, 2024
Sponsor: University of Basel
Reproductive Sterility
Switzerland
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2Active Not Recruiting
NCT01996267Phase 3Updated Mar 29, 2024
Sponsor: The Netherlands Cancer Institute
Breast Cancer · HER2 Positive
Netherlands
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)Completed
NCT02951767Phase 2Updated Mar 28, 2024
Sponsor: Hoffmann-La Roche
Bladder Cancer
United States, Canada, France, Germany, Italy +3 more
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)Completed
NCT02108652Phase 2Updated Mar 28, 2024
Sponsor: Hoffmann-La Roche
Bladder Cancer
United States, Canada, France, Germany, Italy +3 more
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerCompleted
NCT04177108Phase 3Updated Mar 27, 2024
Sponsor: Hoffmann-La Roche
Triple-Negative Breast Cancer
United States, Argentina, Australia, Austria, Belgium +32 more
A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)Terminated
NCT04592341Phase 2Updated Mar 27, 2024
Sponsor: Hoffmann-La Roche
Alzheimer Disease
United States, Belgium, France, Germany, Italy +3 more
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple SclerosisCompleted
NCT02545868Phase 3Updated Mar 26, 2024
Sponsor: Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
United States, Canada
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)Completed
NCT03125902Phase 3Updated Mar 26, 2024
Sponsor: Hoffmann-La Roche
Triple-Negative Breast Cancer
United States, Argentina, Brazil, Canada, China +19 more
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell LymphomaCompleted
NCT04313608Phase 1Updated Mar 25, 2024
Sponsor: Hoffmann-La Roche
B-cell Lymphoma
Australia
Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological MalignanciesUnknown
NCT04470947N/AUpdated Mar 22, 2024
Sponsor: Medical University of Vienna
Advanced Lymphoma · Refractory Lymphoma · Refractory Leukemia · Refractory Acute Myeloid Leukemia
Austria
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult PatientsTerminated
NCT04793399Phase 1, Phase 2Updated Mar 19, 2024
Sponsor: Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica
Chronic Phase-Chronic Myeloid Leukemia
Spain
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's DiseaseCompleted
NCT03977584Phase 2Updated Mar 15, 2024
Sponsor: Hoffmann-La Roche
Alzheimer Disease
Colombia
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal CancerUnknown
NCT01910610Phase 3Updated Mar 12, 2024
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Cancer Metastatic
France, Ireland, Israel
A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor BurdenUnknown
NCT05387616Phase 2Updated Mar 12, 2024
Sponsor: Ludwig-Maximilians - University of Munich
Follicular Lymphoma
Germany
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast CancerCompleted
NCT03337724Phase 3Updated Mar 12, 2024
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Australia, Belgium, Brazil +25 more
Cost-minimization Analysis of Gastric Cancer Treatments in Hong KongCompleted
NCT01679054N/AUpdated Mar 12, 2024
Sponsor: Vivian Wing Yan Lee
Gastric Cancer
Hong Kong

Previous page Next page